COLL News and Press, Collegium Pharmaceutical Inc. From 03/26/20

The government cannot love you, and any politics that works on a different assumption is destined for no good. ”― Jonah Goldberg Today, we take a deeper look at a ' Tier 3 ' name that has been hit hard in the recent market meltdown triggered by Covid-19 despite several pie...

Collegium Pharmaceutical, Inc. (COLL) Q4 2019 Results Conference Call February 27, 2020 05:00 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - President and Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief ...

Collegium Pharmaceutical (NASDAQ: COLL ): Q4 GAAP EPS of -$0.07 beats by $0.03 . More news on: Collegium Pharmaceutical, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza ® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled for Today at 4:30 p.m. E...

STOUGHTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, confirmed today the details of the year-end earnings call, previously announced on February...

– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and Provide Corporate Update – STOUGHTON, Mass., Feb...

February 13, 2020 Palm Beach, FL – February 13, 2020  – Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes… But we all know that the other side of tha...

Collegium Pharmaceutical (NASDAQ: COLL ) has priced its $125M offering of 2.625% convertible senior notes due 2026 at par. The initial conversion rate is 34.2618 common shares per $1,000 principal amount of the notes (~$29.19/share). More news on: Collegium Pharmaceutical, Inc., Healthca...

CTI BioPharma Receives Accelerated Review Tag CTI BioPharma (CTIC) announced that it has received FDA approval for an accelerated review pathway for Pacritinib. The drug candidate is designed for treating myelofibrosis patients suffering from severe thrombocytopenia or low blood platelets....

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered un...